Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Mallinckrodt
Daiichi Sankyo
Cantor Fitzgerald
Fuji
Express Scripts

Generated: August 23, 2019

DrugPatentWatch Database Preview

Litigation Details for Sanofi-Synthelabo v. Apotex Inc. (S.D.N.Y. 2002)

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Sanofi-Synthelabo v. Apotex Inc. (S.D.N.Y. 2002)

Docket   Try a Free Trial Date Filed 2002-03-21
Court District Court, S.D. New York Date Terminated 2010-10-19
Cause 35:271 Patent Infringement Assigned To Sidney H. Stein
Jury Demand Plaintiff Referred To
Parties APOTEX CORP.; APOTEX INC.; BRISTOL-MYERS SQUIBB COMPANY; BRISTOL-MYERS SQUIBB SANOFI PHARMACEUTICALS HOLDING PARTNERSHIP; DR. ANDREW G. BODNAR; DR. REDDY'S LABORATORIES, INC.; DR. REDDY'S LABORATORIES, LTD.; NATIONAL ASSOCIATION OF CHAIN DRUG STORES; SANOFI-AVENTIS; SANOFI-SYNTHELABO; SANOFI-SYNTHELABO INC.
Patents 4,529,596; 4,847,265; 5,576,328; 5,641,803; 5,670,537; 6,150,365
Attorneys Anthony F Lo Cicero; Bruce J. Chasan; Evan R Chesler; Jonathan Jay Faust; Lawrence S. Bader; Mona Gupta; Richard J Stark; Robert Louis Baechtold; Robert S. Silver; Thomas H. Beck; Zachary R. Davis
Firms Hangley Aronchick Segal & Pudlin; Morvillo Abramowitz Grand Iason Anello & Bohrer, P.C.
Link to Docket External link to docket
Small Molecule Drugs cited in Sanofi-Synthelabo v. Apotex Inc.
The small molecule drugs covered by the patents cited in this case are   Try a Free Trial ,   Try a Free Trial , and   Try a Free Trial .

Details for Sanofi-Synthelabo v. Apotex Inc. (S.D.N.Y. 2002)

Date Filed Document No. Description Snippet Link To Document
2005-10-18 189 Reply CONSTRUCTION OF CLAIMS 1,2,8, 11 AND 12 of U.S. Patent 4,529,596. Document filed by Apotex Inc., Apotex Corp…2002 19 October 2010 1:02-cv-02255-SHS Patent Plaintiff District Court, S.D External link to document
2005-10-31 190 Response Construction of Claims 1,2,8,11 and 12 of U.S. Patent No. 4,529,596 (Apotex Motion NO. 32). Document filed by…2002 19 October 2010 1:02-cv-02255-SHS Patent Plaintiff District Court, S.D External link to document
2006-08-17 266 Exhibit A - E litigations between them involving U.S. Patent No. 4,847,265, 02CV-2255 and 05CV-3965, on the following… litigations between them involving U.S. Patent No, 4,847,265, 02CV-2255 and 05CV-3965, on the following…Evaluations.” W. “Patent Infiingement” means infringement of any patent or of any filed patent application,…reexamination, patent term restoration, or patents of addition and extensions thereof X. “Patent Infringement… EE. “Taxol Patent” means one or more of (i) U.S. Patent No. 5,670,537, (ii) U.S. Patent No. 5,641,803 External link to document
2006-08-31 304 Memorandum & Opinion bisulfate falls. This earlier patent, U.S. Patent No. 4,529,596 (“the ‘596 patent”) issued in July 1985, four… (Id. at ¶¶ 8-9.) That patent, U.S. patent number 4,847,265 (“the ‘265 patent”), claims clopidogrel bisulfate…an earlier Sanofi patent, the ‘596 patent. Second, Apotex argues that the ‘265 patent is invalid for obviousness…‘265 patent is anticipated by the earlier ‘596 patent because, it urges, the earlier ‘596 patent both…‘265 patent is invalid because it is anticipated by the ‘596 patent; that is, the earlier patent describes External link to document
2006-09-01 305 Order engaging in any activity that infringes U.S. Patent No. 4,847,265 during the pendency of this action, and …2002 19 October 2010 1:02-cv-02255-SHS Patent Plaintiff District Court, S.D External link to document
2006-09-01 309 Endorsed Letter is Sanofi's own patent: U.S. Potent No. 4,529,596 ("the '596 patent"). The Court agreed…agreed that the '596 patent is prior art to the patent in suit, and moreover noted that "the …invention claimed in the '596 patent, the Court found that the patent includes too many possibilities…the genus claimed in the '596 patent renders the '596 patent a nonanlicipato~y reference as to…#39;596 patent, are, in fact, very few. First, PCR 4099, which is covered by the '596 patent, was h External link to document
2007-06-19 369 Memorandum & Opinion at 3, 13.) The earlier patent, U.S. Patent No. 4,529,596 (“the ‘596 patent”), issued in July 1985 and… European ‘802 Patent U.S. Patent No. 5,989,578 (“the ‘578 patent”) – a patent held by Sanofi …inventors. (Id. at ¶¶ 8-9.) That patent, U.S. Patent No. 4,847,265 (“the ‘265 patent”), claims clopidogrel bisulfate…“the ‘802 patent”) and Canadian Patent No. 1,194,875 (“the ‘875 patent”) over the same class of compounds…, not only was the prior art patent – the ‘596 patent – before the patent examiner during the prosecution External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Accenture
Federal Trade Commission
US Department of Justice
Fuji
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.